Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1474-1479

  Halvorsen, Ole J ^a   Haukaas, Svein A ^b   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P27;

ADULT; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CELL PROLIFERATION; DISEASE COURSE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DEPLETION; PROTEIN EXPRESSION; SEMINAL VESICLE; TUMOR CELL;

CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORIC MONOESTER HYDROLASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECURRENCE; RISK; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0037388601     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Tamura, M., Gu, J., Tran, H., and Yamada, K. M. PTEN gene and integrin signaling in cancer. J. Natl. Cancer Inst. (Bethesda), 91: 1820-1828, 1999.
2. Tsihlias, J., Kapusta, L., and Slingerland, J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med., 50: 401-423, 1999.
3. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., and Mak, T. W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95: 29-39, 1998.
4. 1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA, 95: 15406-15411, 1998.
5. Ali, I. U., Schriml, L. M., and Dean, M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. (Bethesda), 91: 1922-1932, 1999.
6. Gray, I. C., Phillips, S. M., Lee, S. J., Neoptolemos, J. P., Weissenbach, J., and Spurr, N. K. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res., 55: 4800-4803, 1995.
7. Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., and Sidransky, D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res., 57: 4997-5000, 1997.
8. Dong, J. T., Li. C. L., Sipe, T. W., and Frierson, H. F., Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin. Cancer Res., 7: 304-308, 2001.
9. Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., and Sawyers, C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA, 95: 5246-5250, 1998.
10. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., and Sellers, W. R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res., 59: 4291-4296, 1999.
11. Kip1 protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res., 3: 2269-2274, 1997.
12. Yang, R. M., Naitoh, J., Murphy, M., Wang, H. J., Phillipson, J., deKernion, J. B., Loda, M., and Reiter, R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol., 159: 941-945, 1998.
13. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542-548, 1998.
14. Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S. S., Gaudin, P. B., Fazzari, M., Zhang, Z. F., Massague, J., and Scher, H. I. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. (Bethesda), 90: 1284-1291, 1998.
15. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science (Wash. DC), 269: 682-685, 1995.
16. Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., and Ittmann, M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA, 98: 11563-11568, 2001.
17. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi, P. P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet., 27: 222-224, 2001.
18. Halvorsen, O. J., Hostmark, J., Haukaas, S., Hoisaeter, P. A., and Akslen, L. A. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer (Phila.), 88: 416-424, 2000.
19. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
20. Halvorsen, O. J., Haukaas, S., Hoisaeter, P. A., and Akslen, L. A. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res., 21: 4071-4076, 2001.
21. Perren, A., Weng, L. P., Boag, A. H., Ziebold, U., Thakore, K., Dahia, P. L., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., and Eng, C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol., 155: 1253-1260, 1999.
22. Gimm, O., Perren, A., Weng, L. P., Marsh, D. J., Yeh, J. J., Ziebold, U., Gil, E., Hinze, R., Delbridge, L., Lees, J. A., Mutter, G. L., Robinson, B. G., Komminoth, P., Dralle, H., and Eng, C. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol., 156: 1693-1700, 2000.
23. Kurose, K., Zhou, X. P., Araki, T., Cannistra, S. A., Maher, E. R., and Eng, C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol., 158: 2097-2106, 2001.
24. Kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
25. Simon, R., and Altman, D. G. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer, 69: 979-985, 1994.
26. KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin. Cancer Res., 6: 1896-1899, 2000.